California Public Employees Retirement System Sells 5,716 Shares of Haemonetics Co. (NYSE:HAE)

California Public Employees Retirement System decreased its position in Haemonetics Co. (NYSE:HAEGet Rating) by 6.1% during the second quarter, HoldingsChannel reports. The firm owned 88,048 shares of the medical instruments supplier’s stock after selling 5,716 shares during the quarter. California Public Employees Retirement System’s holdings in Haemonetics were worth $5,739,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP raised its position in shares of Haemonetics by 21.5% in the first quarter. Wellington Management Group LLP now owns 6,165,363 shares of the medical instruments supplier’s stock valued at $389,776,000 after purchasing an additional 1,091,484 shares during the period. Capital Research Global Investors increased its position in Haemonetics by 166.1% during the first quarter. Capital Research Global Investors now owns 5,452,006 shares of the medical instruments supplier’s stock worth $344,676,000 after acquiring an additional 3,402,873 shares during the period. Vanguard Group Inc. increased its position in Haemonetics by 0.6% during the first quarter. Vanguard Group Inc. now owns 4,909,896 shares of the medical instruments supplier’s stock worth $310,404,000 after acquiring an additional 28,960 shares during the period. LGT Capital Partners LTD. increased its position in Haemonetics by 2.2% during the second quarter. LGT Capital Partners LTD. now owns 988,149 shares of the medical instruments supplier’s stock worth $64,408,000 after acquiring an additional 21,650 shares during the period. Finally, River Road Asset Management LLC increased its position in Haemonetics by 18.4% during the first quarter. River Road Asset Management LLC now owns 942,341 shares of the medical instruments supplier’s stock worth $59,575,000 after acquiring an additional 146,641 shares during the period. Institutional investors own 98.51% of the company’s stock.

Haemonetics Stock Up 1.2 %

HAE opened at $84.13 on Friday. Haemonetics Co. has a fifty-two week low of $43.50 and a fifty-two week high of $86.48. The company has a debt-to-equity ratio of 1.04, a current ratio of 2.73 and a quick ratio of 1.76. The firm’s fifty day moving average price is $78.81 and its two-hundred day moving average price is $71.15. The company has a market capitalization of $4.26 billion, a P/E ratio of 50.68 and a beta of 0.40.

Insider Activity

In other news, EVP Michelle L. Basil sold 33,798 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $77.89, for a total value of $2,632,526.22. Following the sale, the executive vice president now owns 35,395 shares in the company, valued at approximately $2,756,916.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Michelle L. Basil sold 11,448 shares of the business’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $78.36, for a total value of $897,065.28. Following the sale, the executive vice president now owns 32,635 shares in the company, valued at approximately $2,557,278.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michelle L. Basil sold 33,798 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $77.89, for a total transaction of $2,632,526.22. Following the completion of the sale, the executive vice president now owns 35,395 shares in the company, valued at approximately $2,756,916.55. The disclosure for this sale can be found here. In the last quarter, insiders have sold 45,713 shares of company stock worth $3,566,256. Corporate insiders own 1.65% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Citigroup boosted their target price on shares of Haemonetics from $80.00 to $88.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 8th. Morgan Stanley boosted their target price on shares of Haemonetics from $85.00 to $90.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 8th. Mizuho boosted their target price on shares of Haemonetics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, November 8th. Barrington Research lifted their price target on shares of Haemonetics from $88.00 to $94.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 8th. Finally, StockNews.com started coverage on shares of Haemonetics in a research note on Wednesday, October 12th. They set a “buy” rating on the stock. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $96.17.

About Haemonetics

(Get Rating)

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

See Also

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAEGet Rating).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.